---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020073"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:00:39.453430+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics Q1 net loss $2.7M; ALS data halt progression; Dr. Reddy's deal

## Summary
- Net loss of $2.7M ($0.28 per share) for Q1 2023 vs $1.7M loss in Q1 2022.
- Cash and cash equivalents $16.3M as of March 31, 2023.
- Positive proof-of-concept data for COYA 302 in ALS: halted disease progression at 24 weeks, minimal decline at 48 weeks.
- Entered worldwide agreement with Dr. Reddy's: in-licensed abatacept biosimilar for COYA 302, out-licensed COYA 301 to Dr. Reddy's for certain territories.
- Appointed Arun Swaminathan, Ph.D. as Chief Business Officer; plans to file IND for phase 2 ALS trial in H2 2023.

## SEC filing metadata
- accession: 0000950170-23-020073
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000095017023020073/0000950170-23-020073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000095017023020073/coya-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020073
- JSON: https://secwatch.observer/filing/0000950170-23-020073.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020073.txt

## Key facts
- Earnings Releases
  Coya Therapeutics, Inc. reported the fiscal quarter ended March 31, 2023 results: net income $2.7 million.
  - Period: the fiscal quarter ended March 31, 2023
  - Net income: $2.7 million
  - Result: reported results
  source text: Net loss was $2.7 million for the quarter ended March 31, 2023, compared to net loss of $1.7 million for the quarter ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000095017023020073/0000950170-23-020073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.